These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10365768)

  • 21. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 22. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.
    DiMichele DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S30-3. PubMed ID: 23109404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Investigation and treatment of hemophilia A with inhibitor of factor VIII (author's transl)].
    Fukutake K; Fujimari M; Ukita M; Kitahara T
    Rinsho Ketsueki; 1973 Dec; 14(0):1393-99. PubMed ID: 4807613
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.
    Cid AR; Casaña P; Cabrera N; Haya S; Cortina V; Aznar JA
    Haemophilia; 2007 Mar; 13(2):206-8. PubMed ID: 17286776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIII inhibitory antibody in a patient with combined factor V/factor VIII deficiency.
    Buckner TW; Nielsen BI; Key NS; Ma A
    Haemophilia; 2015 Jan; 21(1):e77-80. PubMed ID: 25472918
    [No Abstract]   [Full Text] [Related]  

  • 28. Solid tumors and factor VIII antibodies.
    Hauser I; Lechner K
    Thromb Haemost; 1999 Sep; 82(3):1005-7. PubMed ID: 10494753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. World registry on factor VIII inhibitor patients: why?
    Aledort LM
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):7-9. PubMed ID: 8480198
    [No Abstract]   [Full Text] [Related]  

  • 30. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
    Scharrer I; Ehrlich HJ
    Haemophilia; 2001 Jul; 7(4):346-8. PubMed ID: 11442637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor VIII inhibitors.
    Gilles JG; Jacquemin MG; Saint-Remy JM
    Thromb Haemost; 1997 Jul; 78(1):641-6. PubMed ID: 9198231
    [No Abstract]   [Full Text] [Related]  

  • 34. Induction of tolerance using porcine factor VIII.
    Hay CR; Laurian Y
    Vox Sang; 1996; 70 Suppl 1():68-9. PubMed ID: 8869473
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of factor VIII after inhibitor clearance in patients with moderate haemophilia A: a case series.
    Tran DQ; Harvey RD; Meeks SL; Chapman R; Kempton CL
    Haemophilia; 2014 Jul; 20(4):e344-6. PubMed ID: 24750497
    [No Abstract]   [Full Text] [Related]  

  • 36. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
    Seremetis SV
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
    [No Abstract]   [Full Text] [Related]  

  • 37. [Acquired factor VIII deficiency treated with cyclosporine].
    Leinøe EB; Jørgensen M; Nielsen JD
    Ugeskr Laeger; 1999 Aug; 161(34):4762-3. PubMed ID: 10500467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.
    Verbruggen B; Novakova I; Wessels H; Boezeman J; van den Berg M; Mauser-Bunschoten E
    Thromb Haemost; 1995 Feb; 73(2):247-51. PubMed ID: 7792738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate].
    Aznar JA; Jorquera JI; Marty ML
    Sangre (Barc); 1983; 28(3):265-79. PubMed ID: 6414098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.